Completed PHASE1 INTERVENTIONAL 1-arm NCT01608009

[18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer (PAZPET-1)

Phase 1b Exploratory Study of [18F]Fluciclatide-PET as a Marker of Angiogenic Response to Combination Therapy With the Pan-VEGF Inhibitor, Pazopanib, and Weekly Paclitaxel in Platinum Resistant Ovarian Cancer

Sponsor: GlaxoSmithKline

Conditions Ovarian Neoplasm

Interventions Pazopanib and paclitaxel

Updated 6 times since 2017 Last updated: Mar 9, 2017 Started: Jul 31, 2012 Primary completion: May 31, 2015 Completion: Apr 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Ovarian Neoplasm and is currently completed. GlaxoSmithKline leads this study, which shows 6 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Apr 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Apr 2017 [monthly]

Active Not Recruiting PHASE1

First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Imperial College London

Data source: Imperial College London

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom
• Southend, United Kingdom